SUPPLEMENTARY TABLE 2. Age-adjusted incidence\* of cancer,† among persons aged <20 years, by type and U.S. Census region§ — United States,¶ 2003–2014

|  |  |  |
| --- | --- | --- |
| **Cancer type by ICCC group** | **Total** | **U.S. Census region** |
| **Northeast** | **Midwest** | **South** | **West** |
| **No.** | **Rate (95% CI)** | **No.** | **Rate (95% CI)** | **No.** | **Rate (95% CI)** | **No.** | **Rate (95% CI)** | **No.** | **Rate (95% CI)** |
| I Leukemias, myeloproliferative & myelodysplastic diseases | 44,814 | 45.7 (45.3–46.1) | 7,809 | 47.0 (46.0–48.1) | 9,486 | 44.0 (43.1–44.8) | 16,062 | 43.6 (42.9–44.3) | 11,457 | 49.9 (49.0–50.8) |
|  I(a) Lymphoid leukemias | 32,394 | 33.2 (32.8–33.5) | 5,605 | 34.0 (33.1–34.9) | 6,863 | 31.9 (43.1–32.7) | 11,288 | 30.7 (30.1–31.3) | 8,638 | 37.7 (36.9–38.5) |
|  I(b) Acute myeloid leukemias | 7,426 | 7.5 (7.4–7.7) | 1,270 | 7.5 (7.1–7.9) | 1,616 | 7.4 (43.1–7.8) | 2,702 | 7.3 (7.0–7.6) | 1,838 | 8.0 (7.6–8.3) |
|  I(c) Chronic myeloproliferative diseases | 2,301 | 2.3 (2.2–2.4) | 466 | 2.7 (2.5–3.0) | 407 | 1.8 (43.1–2.0) | 1,000 | 2.7 (2.5–2.9) | 428 | 1.9 (1.7–2.0) |
|  I(d) Myelodysplastic syndrome and other myeloproliferative | 1,366 | 1.4 (1.3–1.5) | 249 | 1.5 (1.3–1.7) | 333 | 1.5 (43.1–1.7) | 491 | 1.3 (1.2–1.5) | 293 | 1.3 (1.1–1.4) |
|  I(e) Unspecified and other specified leukemias | 1,327 | 1.4 (1.3–1.4) | 219 | 1.3 (1.1–1.5) | 267 | 1.2 (43.1–1.4) | 581 | 1.6 (1.5–1.7) | 260 | 1.1 (1.0–1.3) |
| II Lymphomas and reticuloendothelial neoplasms | 26,016 | 26.2 (25.9–26.5) | 5,230 | 30.0 (29.2–30.9) | 5,830 | 26.4 (43.1–27.1) | 9,223 | 25.0 (24.5–25.5) | 5,733 | 24.9 (24.3–25.6) |
|  II(a) Hodgkin lymphomas | 12,185 | 12.2 (11.9–12.4) | 2,585 | 14.5 (14.0–15.1) | 2,811 | 12.6 (43.1–13.0) | 4,194 | 11.3 (11.0–11.7) | 2,595 | 11.2 (10.8–11.7) |
|  II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) | 8,630 | 8.7 (8.5–8.9) | 1,748 | 10.1 (9.7–10.6) | 1,821 | 8.3 (43.1–8.7) | 3,142 | 8.5 (8.3–8.9) | 1,919 | 8.4 (8.0–8.8) |
|  II(c) Burkitt lymphoma | 2,377 | 2.4 (2.3–2.5) | 460 | 2.7 (2.5–3.0) | 576 | 2.7 (43.1–2.9) | 812 | 2.2 (2.1–2.4) | 529 | 2.3 (2.1–2.5) |
|  II(d) Miscellaneous lymphoreticular neoplasms | 2,499 | 2.6 (2.5–2.7) | 386 | 2.4 (2.1–2.6) | 555 | 2.6 (43.1–2.8) | 921 | 2.5 (2.3–2.7) | 637 | 2.8 (2.6–3.0) |
|  II(e) Unspecified lymphomas | 325 | 0.3 (0.3–0.4) | 51 | 0.3 (0.2–0.4) | 67 | 0.3 (43.1–0.4) | 154 | 0.4 (0.4–0.5) | 53 | 0.2 (0.2–0.3) |
| III CNS and misc intracranial and intraspinal neoplasms | 30,217 | 30.9 (30.6–31.3) | 5,732 | 34.4 (33.5–35.3) | 6,763 | 31.3 (43.1–32.1) | 11,251 | 30.7 (30.1–31.3) | 6,471 | 28.3 (27.6–29.0) |
|  III(a) Ependymomas and choroid plexus tumor | 2,561 | 2.6 (2.5–2.7) | 440 | 2.7 (2.4–2.9) | 576 | 2.7 (43.1–2.9) | 931 | 2.5 (2.4–2.7) | 614 | 2.7 (2.5–2.9) |
|  III(b) Astrocytomas | 15,497 | 15.8 (15.6–16.1) | 3,065 | 18.4 (17.7–19.0) | 3,526 | 16.3 (43.1–16.9) | 5,657 | 15.4 (15.0–15.9) | 3,249 | 14.2 (13.7–14.7) |
|  III(c) Intracranial and intraspinal embryonal tumors | 5,906 | 6.1 (5.9–6.2) | 959 | 5.8 (5.5–6.2) | 1,328 | 6.2 (43.1–6.5) | 2,205 | 6.0 (5.8–6.3) | 1,414 | 6.2 (5.9–6.5) |
|  III(d) Other gliomas | 5,169 | 5.3 (5.2–5.4) | 1,076 | 6.4 (6.0–6.8) | 1,115 | 5.2 (43.1–5.5) | 1,959 | 5.4 (5.1–5.6) | 1,019 | 4.5 (4.2–4.8) |
|  III(e) Other specified intracranial/intraspinal neoplasms | 622 | 0.6 (0.6–0.7) | 124 | 0.7 (0.6–0.9) | 139 | 0.6 (43.1–0.8) | 247 | 0.7 (0.6–0.8) | 112 | 0.5 (0.4–0.6) |
|  III(f) Unspecified intracranial and intraspinal neoplasms | 462 | 0.5 (0.4–0.5) | 68 | 0.4 (0.3–0.5) | 79 | 0.4 (43.1–0.5) | 252 | 0.7 (0.6–0.8) | 63 | 0.3 (0.2–0.4) |
| IV Neuroblastoma and other peripheral nervous cell tumors | 8,308 | 8.5 (8.3–8.6) | 1,549 | 9.5 (9.1–10.0) | 1,965 | 9.2 (43.1–9.6) | 3,058 | 8.2 (7.9–8.5) | 1,736 | 7.5 (7.1–7.8) |
|  IV(a) Neuroblastoma and ganglioneuroblastoma | 8,076 | 8.2 (8.1–8.4) | 1,509 | 9.3 (8.9–9.8) | 1,913 | 9.0 (43.1–9.4) | 2,969 | 8.0 (7.7–8.3) | 1,685 | 7.2 (6.9–7.6) |
|  IV(b) Other peripheral nervous cell tumors | 232 | 0.2 (0.2–0.3) | 40 | 0.2 (0.2–0.3) | 52 | 0.2 (43.1–0.3) | 89 | 0.2 (0.2–0.3) | 51 | 0.2 (0.2–0.3) |
| V Retinoblastoma | 3,121 | 3.2 (3.1–3.3) | 529 | 3.3 (3.0–3.6) | 632 | 3.0 (43.1–3.2) | 1,204 | 3.2 (3.0–3.4) | 756 | 3.2 (3.0–3.5) |
| VI Renal tumors | 6,698 | 6.8 (6.7–7.0) | 1,151 | 7.1 (6.7–7.5) | 1,484 | 6.9 (43.1–7.3) | 2,646 | 7.1 (6.9–7.4) | 1,417 | 6.1 (5.8–6.5) |
|  VI(a) Nephroblastoma and other nonepithelial renal tumors | 6,070 | 6.2 (6.1–6.4) | 1,042 | 6.4 (6.1–6.8) | 1,352 | 6.3 (43.1–6.7) | 2,365 | 6.4 (6.1–6.6) | 1,311 | 5.7 (5.4–6.0) |
|  VI(b) Renal carcinomas | 594 | 0.6 (0.6–0.7) | 109 | 0.6 (0.5–0.8) | 126 | 0.6 (43.1–0.7) | 258 | 0.7 (0.6–0.8) | 101 | 0.4 (0.4–0.5) |
|  VI(c) Unspecified malignant renal tumors | 34 | 0.0 (0.0–0.1) | —\*\* | — | — | — | 23 | 0.1 (0.0–0.1) | — | — |
| VII Hepatic tumors | 2,305 | 2.3 (2.2–2.4) | 419 | 2.5 (2.3–2.8) | 486 | 2.3 (43.1–2.5) | 818 | 2.2 (2.1–2.4) | 582 | 2.5 (2.3–2.7) |
|  VII(a) Hepatoblastoma | 1,706 | 1.7 (1.7–1.8) | 298 | 1.8 (1.6–2.1) | 367 | 1.7 (43.1–1.9) | 599 | 1.6 (1.5–1.7) | 442 | 1.9 (1.7–2.1) |
|  VII(b) Hepatic carcinomas | 575 | 0.6 (0.5–0.6) | 118 | 0.7 (0.6–0.8) | 116 | 0.5 (43.1–0.6) | 202 | 0.6 (0.5–0.6) | 139 | 0.6 (0.5–0.7) |
|  VII(c) Unspecified malignant hepatic tumors | 24 | 0.0 (0.0–0.0) | — | — | — | — | 17 | 0.1 (0.0–0.1) | — | — |
| VIII Malignant bone tumors | 8,472 | 8.6 (8.4–8.8) | 1,571 | 9.1 (8.6–9.6) | 1,816 | 8.3 (43.1–8.6) | 3,133 | 8.5 (8.2–8.8) | 1,952 | 8.5 (8.2–8.9) |
|  VIII(a) Osteosarcomas | 4,751 | 4.8 (4.7–4.9) | 818 | 4.7 (4.4–5.1) | 1,031 | 4.7 (43.1–5.0) | 1,774 | 4.8 (4.6–5.1) | 1,128 | 4.9 (4.6–5.2) |
|  VIII(b) Chondrosarcomas | 322 | 0.3 (0.3–0.4) | 75 | 0.4 (0.3–0.5) | 69 | 0.3 (43.1–0.4) | 115 | 0.3 (0.3–0.4) | 63 | 0.3 (0.2–0.4) |
|  VIII(c) Ewing tumor and related sarcomas of bone | 2,784 | 2.8 (2.7–2.9) | 542 | 3.2 (2.9–3.4) | 615 | 2.8 (43.1–3.0) | 993 | 2.7 (2.5–2.9) | 634 | 2.8 (2.6–3.0) |
|  VIII(d) Other specified malignant bone tumors | 428 | 0.4 (0.4–0.5) | 99 | 0.6 (0.5–0.7) | 72 | 0.3 (43.1–0.4) | 160 | 0.4 (0.4–0.5) | 97 | 0.4 (0.3–0.5) |
|  VIII(e) Unspecified malignant bone tumors | 187 | 0.2 (0.2–0.2) | 37 | 0.2 (0.2–0.3) | 29 | 0.1 (43.1–0.2) | 91 | 0.3 (0.2–0.3) | 30 | 0.1 (0.1–0.2) |
| IX Soft tissue and other extraosseous sarcomas | 11,530 | 11.7 (11.5–11.9) | 2,115 | 12.4 (11.9–13.0) | 2,519 | 11.5 (43.1–12.0) | 4,259 | 11.6 (11.2–11.9) | 2,637 | 11.5 (11.0–11.9) |
|  IX(a) Rhabdomyosarcomas | 4,495 | 4.6 (4.5–4.7) | 804 | 4.9 (4.5–5.2) | 979 | 4.5 (43.1–4.8) | 1,679 | 4.6 (4.4–4.8) | 1,033 | 4.5 (4.2–4.8) |
|  IX(b) Fibrosarcomas, peripheral nerve & other fibrous | 1,217 | 1.2 (1.2–1.3) | 221 | 1.3 (1.1–1.5) | 295 | 1.3 (43.1–1.5) | 428 | 1.2 (1.1–1.3) | 273 | 1.2 (1.0–1.3) |
|  IX(c) Kaposi sarcoma | 49 | 0.1 (0.0–0.1) | — | — | — | — | 23 | 0.1 (0.0–0.1) | — | — |
|  IX(d) Other specified soft tissue sarcomas | 4,544 | 4.6 (4.5–4.7) | 850 | 4.9 (4.6–5.3) | 975 | 4.4 (43.1–4.7) | 1,629 | 4.4 (4.2–4.6) | 1,090 | 4.7 (4.5–5.0) |
|  IX(e) Unspecified soft tissue sarcomas | 1,225 | 1.2 (1.2–1.3) | 227 | 1.3 (1.2–1.5) | 262 | 1.2 (43.1–1.4) | 500 | 1.4 (1.2–1.5) | 236 | 1.0 (0.9–1.2) |
| X Germ cell & trophoblastic tumors & neoplasms of gonads | 10,992 | 11.0 (10.7–11.2) | 1,906 | 10.8 (10.3–11.3) | 2,445 | 11.0 (43.1–11.4) | 3,735 | 10.0 (9.7–10.4) | 2,906 | 12.5 (12.0–13.0) |
|  X(a) Intracranial & intraspinal germ cell tumors | 1,626 | 1.7 (1.6–1.7) | 287 | 1.7 (1.5–1.9) | 337 | 1.5 (43.1–1.7) | 551 | 1.5 (1.4–1.6) | 451 | 2.0 (1.8–2.2) |
|  X(b) Extracranial & extragonadal germ cell tumors | 1,431 | 1.4 (1.4–1.5) | 251 | 1.5 (1.3–1.7) | 294 | 1.4 (43.1–1.5) | 531 | 1.4 (1.3–1.5) | 355 | 1.5 (1.4–1.7) |
|  X(c) Malignant gonadal germ cell tumors | 7,189 | 7.1 (7.0–7.3) | 1,235 | 6.9 (6.5–7.3) | 1,653 | 7.3 (43.1–7.7) | 2,370 | 6.4 (6.1–6.6) | 1,931 | 8.3 (7.9–8.7) |
|  X(d) Gonadal carcinomas | 429 | 0.4 (0.4–0.5) | 76 | 0.4 (0.3–0.5) | 101 | 0.5 (43.1–0.6) | 147 | 0.4 (0.3–0.5) | 105 | 0.5 (0.4–0.6) |
|  X(e) Other and unspecified malignant gonadal tumors | 317 | 0.3 (0.3–0.4) | 57 | 0.3 (0.3–0.4) | 60 | 0.3 (43.1–0.4) | 136 | 0.4 (0.3–0.4) | 64 | 0.3 (0.2–0.4) |
| XI Other malignant epithelial neoplasms and melanomas†† | 17,916 | 17.8 (17.6–18.1) | 3,734 | 20.9 (20.2–21.6) | 4,083 | 18.2 (43.1–18.8) | 6,126 | 16.5 (16.1–16.9) | 3,973 | 17.1 (16.6–17.7) |
|  XI(a) Adrenocortical carcinomas | 208 | 0.2 (0.2–0.2) | 34 | 0.2 (0.1–0.3) | 51 | 0.2 (43.1–0.3) | 77 | 0.2 (0.2–0.3) | 46 | 0.2 (0.2–0.3) |
|  XI(b) Thyroid carcinomas | 7,866 | 7.8 (7.6–8.0) | 1,854 | 10.3 (9.9–10.8) | 1,734 | 7.7 (43.1–8.1) | 2,481 | 6.7 (6.4–7.0) | 1,797 | 7.7 (7.4–8.1) |
|  XI(c) Nasopharyngeal carcinomas | 557 | 0.6 (0.5–0.6) | 93 | 0.5 (0.4–0.6) | 110 | 0.5 (43.1–0.6) | 255 | 0.7 (0.6–0.8) | 99 | 0.4 (0.4–0.5) |
|  XI(d) Malignant melanomas | 4,853 | 4.8 (4.7–5.0) | 916 | 5.2 (4.8–5.5) | 1,157 | 5.2 (43.1–5.5) | 1,693 | 4.6 (4.3–4.8) | 1,087 | 4.7 (4.4–5.0) |
|  XI(f) Other and unspecified carcinomas | 4,349 | 4.3 (4.2–4.5) | 828 | 4.7 (4.3–5.0) | 1,010 | 4.5 (43.1–4.8) | 1,583 | 4.3 (4.1–4.5) | 928 | 4.0 (3.8–4.3) |
| XII Other and unspecified malignant neoplasms | 785 | 0.8 (0.7–0.9) | 122 | 0.7 (0.6–0.9) | 145 | 0.7 (43.1–0.8) | 377 | 1.0 (0.9–1.1) | 141 | 0.6 (0.5–0.7) |
|  XII(a) Other specified malignant tumors | 368 | 0.4 (0.3–0.4) | 64 | 0.4 (0.3–0.5) | 92 | 0.4 (43.1–0.5) | 131 | 0.4 (0.3–0.4) | 81 | 0.4 (0.3–0.4) |
|  XII(b) Other unspecified malignant tumors | 417 | 0.4 (0.4–0.5) | 58 | 0.3 (0.3–0.4) | 53 | 0.2 (43.1–0.3) | 246 | 0.7 (0.6–0.8) | 60 | 0.3 (0.2–0.3) |
| Not classified by ICCC or in situ | 258 | 0.3 (0.2–0.3) | 26 | 0.2 (0.1–0.2) | 48 | 0.2 (43.1–0.3) | 106 | 0.3 (0.2–0.4) | 78 | 0.3 (0.3–0.4) |

Source: CDC’s National Program of Cancer Registries and the NCI’s Surveillance, Epidemiology, and End Results Program.

Abbreviations: CI = confidence interval, ICCC= International Classification of Childhood Cancer.

\* Rates are per 1 million persons and age-adjusted to the 2000 U.S. Standard population.

† Cases included all malignant cancers (with behavior code = 3) as grouped by the ICCC.

§ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming

¶ Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded. Registry-specific data quality information is available at <https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2014-technical-notes.pdf>.